MENLO PARK, Calif., June 07, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California Inc., (Nasdaq:PACB) today announced that obtaining microbial genomes with high accuracy and contiguity has become faster and more affordable thanks to new multiplexing tools it will feature at the upcoming American Society for Microbiology (ASM) annual meeting in Atlanta. The increased throughput of... Read more
HINXTON, United Kingdom and MENLO PARK, Calif., June 06, 2018 (GLOBE NEWSWIRE) — The genomes of more than 3,000 bacteria, including some of the world’s most dangerous, have been sequenced by researchers at the Wellcome Sanger Institute in collaboration with Pacific Biosciences (PacBio). Infecting tens of millions of people worldwide every year, these bacteria have... Read more
New open-source algorithm produces phased diploid genome assemblies SEATTLE, May 21, 2018 /PRNewswire/ — Seattle-based Phase Genomics [www.phasegenomics.com], the leader in Hi-C based genomic solutions and Pacific Biosciences of California, Inc. [www.pacb.com], the leader in long-read sequencing, announce the release of the FALCON-Phase software as part of a new co-development effort to improve the FALCON-Unzip genome assembly method for providing high-quality,... Read more
MENLO PARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced that it has entered into a five-year settlement agreement with Oxford Nanopore and other parties of patent infringement litigation between the parties in the United Kingdom and Germany, under which Oxford Nanopore... Read more
Wed 9th May 2018 Oxford Nanopore and Pacific Biosciences have agreed to discontinue UK and German litigation. In the settlement, Oxford Nanopore agreed not to sell its 2D kits in UK and Germany. 2D is, in any case, obsolete and was globally discontinued in May 2017, when Oxford Nanopore replaced it with the superior 1D^2... Read more
MENLO PARK, Calif., April 11, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced that the HudsonAlpha Institute for Biotechnology is using the organization’s newest Sequel® Sequencing System to support the goal of dramatically increasing the diagnostic success rate in challenging pediatric clinical cases. Led by... Read more
MENLO PARK, Calif., March 27, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced a purchase order for 10 PacBio® Sequel® Systems that are expected to be installed at Annoroad’s designated facility within the next several months, enhancing Annoroad’s large-scale genomic service capabilities across various fields... Read more
MENLO PARK, Calif., March 22, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced that Judge Leonard P. Stark of the U.S. District Court for the District of Delaware denied a motion to dismiss filed on December 14, 2017 by Oxford Nanopore Technologies, Inc., a wholly-owned... Read more
MENLO PARK, Calif., March 15, 2018 (GLOBE NEWSWIRE) — A new publication in the journal of the American Society of Gene & Cell Therapy demonstrates the utility of Single Molecule, Real-Time (SMRT®) Sequencing to assess the quality of viral vector preparations for clinical and basic research, with the ultimate goal of improving the safety and... Read more
MENLO PARK, Calif., March 13, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 9,910,956 (the “956 Patent”), entitled “Sequencing using concatemers of copies of sense and antisense strands.” The 956 Patent was... Read more